Notable Adverse Events from TRuE-V Studies
Key adverse events from the TRuE-V studies are highlighted.
In this segment of the discussion on vitiligo, Gary Owens, M.D., and David Rosmarin, M.D.,delve into the adverse events associated with the long-term use of the drug ruxolitinib. They emphasize the importance of considering both efficacy and safety in drug evaluation. Notably, they highlight that there have been no new side effects observed in the long-term extension of the study that were not previously seen in the initial phase. They discuss the similarities in infection results between patients initially using ruxolitinib cream and those switched from a vehicle to the medication. The experts express their views that the reported adverse events are likely random occurrences, not directly related to the treatment. They specifically mention the common occurrences of application site acne and pruritus. Overall, the discussion underscores the safety profile of the drug, emphasizing its topical nature and limited impact on the body surface area.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
